RapidEye
Immutep (NASDAQ:IMMP) reported encouraging preliminary topline results from a Phase 2 study for its drug candidate eftilagimod alpha, or efti, in combination with Merck’s (MRK) blockbuster cancer drug Keytruda in the treatment of a type of head and neck cancer.
The study has been testing the efti/Keytruda combination as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma with negative PD-L1 expression.
The Australian immunotherapy developer said the Cohort B portion of the study TACTI-003 demonstrated an overall response rate of 26.9% and disease control rate of 57.7% in 26 patients whose tumors did not express PD-L1.
Immuntep said it expects to release data on the primary endpoint for Cohort A and B in the first half of 2024.
